BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 14512000)

  • 1. Long term angiotensin converting enzyme-inhibition in patients after coronary artery bypass grafting reduces levels of soluble intercellular cell adhesion molecule-1.
    van Haelst PL; Tervaert JW; van Geel PP; Veeger NJ; Gurné O; Gans RO; van Gilst WH
    Eur J Vasc Endovasc Surg; 2003 Oct; 26(4):387-91. PubMed ID: 14512000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia.
    Oosterga M; Voors AA; Pinto YM; Buikema H; Grandjean JG; Kingma JH; Crijns HJ; van Gilst WH
    Am J Cardiol; 2001 Mar; 87(5):542-6. PubMed ID: 11230836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of angiotensin converting enzyme inhibition on myocardial function and blood pressure after coronary artery bypass surgery--a randomised study.
    Webb CM; Underwood R; Anagnostopoulos C; Bennett JG; Pepper J; Lincoln C; Collins P
    Eur J Cardiothorac Surg; 1998 Jan; 13(1):42-8. PubMed ID: 9504729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of preoperative C-reactive protein and soluble intercellular adhesion molecule-1 level for predicting future cardiovascular events after coronary artery bypass grafting.
    van der Harst P; Voors AA; Volbeda M; Buikema H; van Veldhuisen DJ; van Gilst WH
    Am J Cardiol; 2006 Jun; 97(12):1697-701. PubMed ID: 16765116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial.
    Cashin-Hemphill L; Holmvang G; Chan RC; Pitt B; Dinsmore RE; Lees RS
    Am J Cardiol; 1999 Jan; 83(1):43-7. PubMed ID: 10073783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
    Mancini GB; Henry GC; Macaya C; O'Neill BJ; Pucillo AL; Carere RG; Wargovich TJ; Mudra H; Lüscher TF; Klibaner MI; Haber HE; Uprichard AC; Pepine CJ; Pitt B
    Circulation; 1996 Aug; 94(3):258-65. PubMed ID: 8759064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction.
    Schlaifer JD; Mancini GB; O'Neill BJ; Pitt B; Haber HE; Pepine CJ
    Cardiovasc Drugs Ther; 1999 May; 13(3):201-9. PubMed ID: 10439882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ischemia Management with Accupril post bypass Graft via Inhibition of angiotensin coNverting enzyme (IMAGINE): a multicentre randomized trial - design and rationale.
    Warnica JW; Gilst WV; Baillot R; Johnstone D; Block P; Myers MG; Chocron S; Ave SD; Martineau P; Rouleau JL
    Can J Cardiol; 2002 Nov; 18(11):1191-200. PubMed ID: 12464983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The QUinapril Ischemic Event Trial (QUIET) design and methods: evaluation of chronic ACE inhibitor therapy after coronary artery intervention.
    Texter M; Lees RS; Pitt B; Dinsmore RE; Uprichard AC
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):273-82. PubMed ID: 8357782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
    Pitt B; O'Neill B; Feldman R; Ferrari R; Schwartz L; Mudra H; Bass T; Pepine C; Texter M; Haber H; Uprichard A; Cashin-Hemphill L; Lees RS;
    Am J Cardiol; 2001 May; 87(9):1058-63. PubMed ID: 11348602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators.
    Pflugfelder PW; Baird MG; Tonkon MJ; DiBianco R; Pitt B
    J Am Coll Cardiol; 1993 Nov; 22(6):1557-63. PubMed ID: 8227822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating intercellular cell adhesion molecule-1, endothelin-1 and von Willebrand factor-markers of endothelial dysfunction in uncomplicated essential hypertension: the effect of treatment with ACE inhibitors.
    Hlubocká Z; Umnerová V; Heller S; Peleska J; Jindra A; Jáchymová M; Kvasnicka J; Horký K; Aschermann M
    J Hum Hypertens; 2002 Aug; 16(8):557-62. PubMed ID: 12149661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin converting enzyme inhibitors and restenosis: let's stop teasing ourselves.
    Mancini GB
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):293-5. PubMed ID: 11800410
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
    Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
    Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinapril with high affinity to tissue angiotensin-converting enzyme reduces restenosis after percutaneous transcatheter coronary intervention.
    Okimoto T; Imazu M; Hayashi Y; Gomyo Y; Sekiguchi Y; Yanagihara K; Shimohara Y; Sumii K; Yamamoto H; Tadehara F; Toyofuku M; Kohno N
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):323-9. PubMed ID: 11800416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.
    Culy CR; Jarvis B
    Drugs; 2002; 62(2):339-85. PubMed ID: 11817979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does blood pressure reduction necessarily compromise cardiac function or renal hemodynamics? Effects of the angiotensin-converting enzyme inhibitor quinapril.
    Kjeldsen SE; Gupta RK; Krause L; Weder AB; Julius S
    Am Heart J; 1992 May; 123(5):1433-8. PubMed ID: 1575171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
    Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
    Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinapril therapy in patients with chronic mitral regurgitation.
    Schön HR; Schröter G; Barthel P; Schömig A
    J Heart Valve Dis; 1994 May; 3(3):303-12. PubMed ID: 8087269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of angiotensin-converting enzyme inhibition on transient ischemia: the Quinapril Anti-Ischemia and Symptoms of Angina Reduction (QUASAR) trial.
    Pepine CJ; Rouleau JL; Annis K; Ducharme A; Ma P; Lenis J; Davies R; Thadani U; Chaitman B; Haber HE; Freedman SB; Pressler ML; Pitt B;
    J Am Coll Cardiol; 2003 Dec; 42(12):2049-59. PubMed ID: 14680725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.